The present invention relates to device (10) for determining a fibrinogen level (20) in a sample (22) comprising, a first input for obtaining an attenuance signal (24) over time indicative of a fibrin polymerization of said sample (22), a second input for obtaining a reactant concentration signal (28) over time indicative of a reactant concentration in said sample (22), wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit (16) running a model (32) using the reactant concentration signal (28) as an input to provide a simulated attenuance signal (34) over time, and an evaluation unit (18) configured to infer the fibrinogen level (20) of said sample (22) by comparing the attenuance signal (24) over time with the simulated attenuance signal (34) over time.

A blood analyzing method includes optically measuring a first calibration sample prepared from a fibrin/fibrinogen degradation product (FDP) measurement reagent and a first calibrator containing D-dimer (DD) and having a first value relating to the ratio of the content of FDP to the content of DD, acquiring first calculation data based on temporal change of optical information of the first calibration measurement sample, performing optical measurement of a second calibration measurement sample prepared from FDP measurement reagent and a second calibrator containing DD and having a second value that is different from the first value, acquiring second calculated data based on a temporal change in optical information of the second calibration measurement sample, and acquiring calibration curve information indicating the relationship between the calculation data and the value relating to the amount of DD.

Systems and methods for imaging and tracking fibrin formation via interaction of a test sample with a clotting agent or for imaging and tracking fibrin removal by an anti-clotting agent are described.In certain embodiments, the systems (200) comprise a planar reflective substrate (222, 224) comprising one or more capture agents and/or one or more fibrin reference regions; a mount for holding the substrate; an illumination light source (201) for directing illumination light toward a top surface of the substrate with fibrin (226)formed thereon; an image detector (232, 234) aligned with respect to the mount for detecting a portion of the illumination light that is scattered by the fibrin, and/or reflected by the reflective substrate, thereby obtaining a label-free image of fibrin formation or fibrin removal; a processor of a computing device (240); and a memory having instructions stored thereon, wherein the instructions, when executed by the processor, cause the processor to: receive and/or access data corresponding to the one or more label free images, and use the one or more label-free images to determine one or more measures of fibrin formation or fibrin removal.

A method of measuring an analyte amount in a whole blood sample, including (i) measuring the haematocrit level of the whole blood sample; (ii) measuring an analyte amount directly in the whole blood sample; and (iii) calculating a corrected analyte amount according to relation D.sub.P=P.sub.a(D.sub.ST, D.sub.H), where D.sub.p, is the corrected analyte amount, D.sub.ST is the measured analyte amount, D.sub.H is the measured haematocrit level, and P.sub.a is a non-constant polynomial of a degree greater than or equal to 1 having as indeterminate values the measured analyte amount, D.sub.ST, and the measured haematocrit level, D.sub.H, and having its polynomial coefficients depending on the analyte.

Disclosed herein are methods and compositions for inhibiting, preventing, ameliorating, reducing, or treating cardiovascular diseases, for example, stroke, traumatic brain injury, cerebral amyloid angiopathy, atherosclerosis, myocardial infarction, and/or diseases associated with fibrin activity or dysfunction. These methods and compositions involve antibodies that can bind to Galectin-3 and inhibit, prevent, ameliorate, reduce, or treat the cardiovascular diseases in a patient by reducing inflammation and/or inhibiting oligomerization of proteins associated with pathology such as amyloid beta or fibrin.

Disclosed is an apparatus for testing blood coagulation indicators, including a blood sample receiving and preprocessing unit, and the blood preprocessing part is configured to remove or neutralize the anticoagulation effect of the artificially added anticoagulant in the blood sample; a reacting unit in which the blood undergoes a clotting process; a blood coagulation indicator analyzing and computing unit which may measure an electrical signal passing through the blood sample during the course of testing to obtain measurement results reflecting a time measurement function; and a result displaying unit. Further disclosed is a method for testing coagulation indicators of a blood sample using the apparatus.

A biomarker panel including a four-panel test for clotting that detects soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), and plasminogen activator inhibitor (PAI-1). A biomarker panel including a three-panel test for glycocalyx integrity that detects syndecan-1 (SDC1), heparan sulfate (HS), and hyaluronidase (HAD). A biomarker panel including a test that detects a biomarker chosen from soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), plasminogen activator inhibitor (PAI-1), syndecan-1 (SDC1), heparan sulfate (HS), hyaluronidase (HAD), and combinations thereof. A kit including a biomarker panel, instructions for use, materials to take and apply samples to the panel, and descriptions of biomarker levels and their meaning. Methods of detecting the presence of vascular disease, determining the stage of vascular disease, monitoring the progress of vascular disease treatments, and monitoring the efficacy of drugs during drug development.

Provided is a sensitive and specific LC-MS-MRM quantification method that distinguishes outer-arm and core fucosylated configurations of N-glycopeptides. Advantage is taken of limited fragmentation of the glycopeptides at low collision energy (collision-induced dissociation) CID to produce linkage-specific Y-ions. These ions are selected as multiple reaction monitoring (MRM) transitions for the quantification of the outer-arm and total fucosylation of 23 glycoforms of 9 glycopeptides in 7 plasma proteins. The method permits quantification of the glycoforms directly in plasma or serum without fractionation of samples or glycopeptide enrichment. A pilot study of fucosylation in liver cirrhosis of hepatitis C vims (HCV) and non-alcoholic steatohepatitis (NASH) etiologies demonstrated that liver cirrhosis is consistently associated with increased outer-arm fucosylation of a majority of the analyzed proteins. The outer-arm fucosyaltion of the A2G2F1 glycoform of the VDKDLQSLEDILHQVENK peptide of fibrinogen was found to increase more than 10-fold in the cirrhosis patients compared to healthy controls.

An object of the present invention is to provide a pharmaceutical composition or food or drink composition comprising an active ingredient that suppresses functional expression of Oscar protein. Another object of the present invention is to provide a pharmaceutical composition or food composition for preventing or treating kidney disease. A further object of the present invention is to provide a pharmaceutical composition or food or drink composition that suppresses functional expression of Oscar in a living organism in order to suppress functional expression of FGF23. A still further object of the present invention is to provide a method for evaluating an effect, in the body, of an active ingredient that suppresses functional expression of Oscar protein. The above objects are achieved by at least one member selected from the group consisting of antagonists of the Oscar protein; genome editing systems that target Oscar gene; at least one RNA molecule selected from the group consisting of siRNA, shRNA, and miRNA that target Oscar mRNA, or vectors capable of expressing the RNA molecule; and antibodies that specifically bind to the Oscar protein and suppress function of the Oscar.

A blood state analysis apparatus including at least an analysis unit that uses data related to the temporal change in electrical characteristics to analyze information related to fibrinogen in a blood sample, in which the analysis unit uses at least two predetermined time points derived from the data related to the temporal change on a basis of a predetermined mathematical definition to calculate a parameter R, and acquires at least two pieces of information related to the fibrinogen in the blood sample.